glp 1 and visceral fat loss Still Have Stubborn After GLP1? We Have the Solution! Juzer Husaini DO | ⚠️

My cravings were reduced, my energy was more consistent, and I began to feel like myself againmore focused, more balanced, and more in control

In clinical trials, retatrutide has shown weight loss exceeding 24% of body weight, surpassing both semaglutide and tirzepatide

Veterans Affairs (VA) analysis published in JAMA Ophthalmology , semaglutide use was associated with approximately double the risk of nonarteritic anterior ischemic optic neuropathy (NAION) compared with SGLT2 inhibitors in patients with type 2 diabetes. The study followed more than 102,000 patients for up to seven years, making it the most comprehensive assessment so far of this potential association

Although these symptoms are uncommon, early evaluation remains important for overall thyroid health

Retatrutide Peptide Guide: Illustrative Research Case Studies The following examples are illustrative research scenarios based on themes commonly reported in preclinical metabolic research